Fishman, M. (2019). Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer (“KEYNOTE 045”). Transl Androl Urol.
शिकागो स्टाइल उद्धरणFishman, Mayer. "Commentary: 2-year Follow Up of Pembrolizumab As Second-line Therapy for Advanced Urothelial Cancer (“KEYNOTE 045”)." Transl Androl Urol 2019.
एमएलए उद्धरणFishman, Mayer. "Commentary: 2-year Follow Up of Pembrolizumab As Second-line Therapy for Advanced Urothelial Cancer (“KEYNOTE 045”)." Transl Androl Urol 2019.
चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.